$VRAX News

Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

Virax Biolabs Files Prospectus For Offering 1.682M Ordinary Shares

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs Management Believes Current Valuation Doesn't Fully Reflect Its Audited Financial Position, Clinical And Development Programs, Commercial Progress Or Strategic Assets

Virax Biolabs enters immune profiling product supply deal with Fosun

Virax Biolabs enters immune profiling product supply deal with Fosun

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Why Did Virax Biolabs Stock Triple In One Session?

Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX)

Virax Biolabs Group Signs Agreement For Immediate Exercise Of 548K Shares At $6/Share For ~$3.3M

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

Why Did Virax Biolabs Stock Triple In One Session?

Virax Biolabs Group Unit Enters Into Exclusive Multi-Country Commercial Supply Agreement With Fosun Diagnostics For ImmuneSelect Research-Use Immune Profiling Product Line

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Virax Biolabs Group Announces 1-For-25 Reverse Stock Split, Effective June 26

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders